Answers are grounded in this paper and cite their sources.
Beta-adrenergic receptors (β-ARs) encompass three distinct subtypes, which participate in modulating inflammatory responses. Both agonists and antagonists of these receptors are used to treat numerous diseases and have often been observed to have a protective role on different kinds of tissues. β-AR antagonists are used to treat cardiovascular diseases and chronic obstructive pulmonary disease but may worsen inflammation in neurodegenerative disorders. However, two β-AR antagonists, carvedilol and nebivolol, can attenuate the formation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. Many β-AR agonists have proved to mediate anti-inflammatory signals, especially in regard to suppressing the inflammatory response of macrophages or providing protective effects in cases of hypoxia. The activation of beta-adrenergic receptors can, however, be a double-edged sword, as their overactivation may result in cardiac inflammation. Here, we aim to provide an overview of recent advances in studying the connection between β-ARs and inflammation. • Beta-adrenergic receptors (β-ARs) are involved in a number of inflammatory processes. • Many β-AR ligands have been shown to attenuate NLRP3 inflammasome activation. • β-AR overactivation can promote cardiac inflammation and injury.
No takes yet. Share an insight, caveat, or question.
Dragan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: